BioNTech’s €17 Billion Transformation Gamble Faces a Defining May

The clock is ticking for BioNTech. After a 30-day rally that has pushed its stock up 23% to €92.70, the Mainz-based biotech enters a pivotal month that will test whether its massive cash pile can be converted into a viable oncology powerhouse. The shares have climbed nearly 24% on a monthly basis to €93.10, outpacing a sluggish sector, as investors bet on a strategic overhaul that will reshape the company from a Covid vaccine maker into a pure-play cancer specialist.

A Leadership Exodus and Boardroom Reshuffle

The transformation extends beyond the pipeline. On May 15, shareholders will gather virtually for an annual meeting that promises to redraw the company’s governance. Founders Ugur Sahin and Özlem Türeci are set to depart by the end of 2026, moving to manage their new venture. The supervisory board, currently six-strong, will expand to eight members, with Dr. Susanne Schaffert and Prof. Dr. Iris Loew-Friedrich nominated for election. Both bring oncology and product-launch expertise that the company sorely needs as it pivots away from respiratory vaccines.

A separate vote will test investor appetite for dilution. The board is seeking approval for new authorized capital of roughly €130 million, equivalent to half the current share capital. That war chest is earmarked for the expensive late-stage trials that will determine whether BioNTech’s cancer pipeline can deliver commercially.

Financial Headwinds and a Tax Maneuver

The numbers tell a sobering story. After a modest revenue uptick last year, management expects 2026 sales to slump by about 25% to as low as €2.3 billion. The Covid vaccine Comirnaty, once a cash machine, faces fading demand from shifting immunization guidelines and a move to the private US market. Adding to the pressure, a 15% US tariff on European pharmaceuticals kicks in at the end of July, directly affecting transatlantic production of the shot. BioNTech’s experimental cancer drugs may escape those levies, but the near-term pain is real.

Should investors sell immediately? Or is it worth buying BioNTech?

To soften the blow, the company is seeking a profit-and-loss transfer agreement with its subsidiary BioNTech Discovery GmbH. The parent posted a net loss of €1.14 billion in fiscal 2025, and the arrangement would allow future profits from the unit to offset that deficit for tax purposes. Cost-cutting is also underway: a manufacturing site in Singapore will be wound down by early 2027.

The Oncology Bet Requires Patience

BioNTech’s pivot to oncology is a long game, and management has been candid that 2026 will not yield any commercial revenue from its cancer pipeline. That makes the company’s liquidity cushion all the more critical. At the end of 2025, BioNTech held roughly €17.2 billion in cash and equivalents—enough to fund years of clinical development.

There are glimmers of progress. In April, the company reported positive Phase 2 data for an antibody targeting uterine cancer, and the US Food and Drug Administration has granted the drug a fast-track approval process. But the real test comes on May 5, when BioNTech releases first-quarter results. Analysts will scrutinize the numbers less for the headline revenue and more for the forward guidance on pipeline milestones.

The market’s optimism is reflected in analyst price targets. The median six-month target stands at $130, implying significant upside from current levels. But the next ten days will deliver hard facts: first the quarterly report, then the shareholder votes that will formally greenlight the next phase of BioNTech’s evolution. With €17 billion on the line, the stakes could not be higher.